Skip to content
1887

Access Microbiology open research platform logo Access Microbiology

Volume 6, Issue 7

Investigating the effectiveness of commercially available mouthwash on SARS-CoV-2 using viable virus titre as the primary outcome. A randomised controlled trial Open Access

Abstract

This multi-arm, parallel group, single-blinded randomised controlled trial aimed to assess three commercially available mouthwashes effectiveness against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). This manuscript has been written in accordance with the CONSORT statement.

Eligible participants were SARS-CoV-2 positive with a positive test in the last 72 h. All participants had mild to moderate symptoms and could provide five saliva samples over a 60 min period. Participants delivered a baseline saliva sample and then used a mouthwash as per manufacturer’s instructions. They provided further saliva samples at minute 1, 10, 30 and 60. Participants were randomised to one of four groups; OraWize+, Total Care Listerine, Cool Mint Listerine and water (control). The lab-based research team were blind to the intervention. The research question was: can SARS-CoV-2 be rendered inactive in saliva by using a mouthwash and how long does this effect last? The primary outcome was the amount of viable infectious SARS-CoV-2 virus in the sample, compared to the baseline sample. The secondary outcome measure was the amount of genetic material from the SARS-CoV-2 virus in the sample, measured via PCR testing.

In total 100 participants were recruited (25 per group). Eight participants did not receive the allocated intervention and did not have saliva samples collected. There were no adverse events. In total 42 of the 92 participants had viable virus which could be cultured at baseline. Statistical analysis of the primary outcome was not advised due to the reduced level of viable virus at baseline and the positive skewness present in the distribution of log10(titre) data. Observational data of the primary outcome measure is presented.

Analysis of the secondary outcome PCR measure showed that there was strong evidence for a decrease in SARS-CoV-2 RNA levels compared to water for all mouthwashes after 1 min, OraWize+ −0.49 (−0.92, –0.05), -value 0.029, Cool Mint Listerine −0.81 (−1.25, –0.38), -value<0.001, Total Care Listerine −1.05 (−1.48, –0.62), -value<0.001. For the remaining timepoints there was generally no evidence of virus level reduction compared to water although there is weak evidence for a decrease at ten minutes using Total Care Listerine −0.44 (−0.88, 0.01), -value 0.053.

The three mouthwashes included in this trial observationally demonstrated a reduction in virus titre level 1 min after use, with virus levels normalising up to 60 min compared to the control. Although an interesting observation, this result could not be statistically analysed. Using the secondary outcome PCR measure all three included mouthwashes reduced virus levels compared to water at 1 min and these results were statistically significant. Clinically this result does not support the use of the included mouthwashes to reduce SARS-CoV-2 levels in saliva.

  • Received:
  • Accepted:
  • Published Online:
Keyword(s): mouthwash , saliva and SARS-CoV-2
Funding
This study was supported by the:
  • Johnson and Johnson (Award NA)
    • Principal Award Recipient: DavidWilliam Seymour
© 2024 The Authors
  • This is an open-access article distributed under the terms of the Creative Commons Attribution License. This article was made open access via a Publish and Read agreement between the Microbiology Society and the corresponding author’s institution.
Loading

Article metrics loading...

/content/journal/acmi/10.1099/acmi.0.000722.v3
2024-07-10
2026-03-16

Metrics

Loading full text...

Full text loading...

/deliver/fulltext/acmi/6/7/acmi000722.v3.html?itemId=/content/journal/acmi/10.1099/acmi.0.000722.v3&mimeType=html&fmt=ahah

References

  1. Zhu N, Zhang D, Wang W, Li X, Yang B et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med 2020; 382:727–733 [View Article] [PubMed]
     [Google Scholar]
  2. Huang C, Wang Y, Li X, Ren L, Zhao J et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020; 395:497–506 [View Article] [PubMed]
     [Google Scholar]
  3. To KK, Tsang OT, Yip CC, Chan KH, Wu TC et al. Consistent detection of 2019 novel coronavirus in saliva. Clin Infect Dis 2020; 71:841–843 [View Article] [PubMed]
     [Google Scholar]
  4. Carrouel F, Valette M, Perrier H, Bouscambert-Duchamp M, Dussart C et al. Performance of Self-Collected Saliva Testing Compared with Nasopharyngeal Swab Testing for the Detection of SARS-CoV-2. Viruses 2021; 13:895 [View Article] [PubMed]
     [Google Scholar]
  5. van Doremalen N, Bushmaker T, Morris DH, Holbrook MG, Gamble A et al. Aerosol and surface stability of SARS-CoV-2 as compared with SARS-CoV-1. N Engl J Med 2020; 382:1564–1567 [View Article] [PubMed]
     [Google Scholar]
  6. Retamal-Valdes B, Soares GM, Stewart B, Figueiredo LC, Faveri M. Effectiveness of a pre-procedural mouthwash in reducing bacteria in dental aerosols: randomized clinical trial. Braz Oral Res 2017; 31:e21 [View Article] [PubMed]
     [Google Scholar]
  7. Ramesh A, Thomas JT, Varghese SS, Muralidharan NP. Efficacy of adjunctive usage of hydrogen peroxide with chlorhexidine as preprocedural mouthrinse on dental aerosol. Natl J Physiol Pharm Pharmacol 2015; 5:431–435 [View Article]
     [Google Scholar]
  8. Gupta G, Mitra D, Ashok KP, Gupta A, Soni S et al. Efficacy of preprocedural mouth rinsing in reducing aerosol contamination produced by ultrasonic scaler: a pilot study. J Periodontol 2014; 85:562–568 [View Article] [PubMed]
     [Google Scholar]
  9. Davies K, Buczkowski H, Welch SR, Green N, Mawer D et al. Effective in vitro inactivation of SARS-CoV-2 by commercially available mouthwashes. J Gen Virol 2021; 102:001578 [View Article] [PubMed]
     [Google Scholar]
  10. Muñoz-Basagoiti J, Perez-Zsolt D, León R, Blanc V, Raïch-Regué D et al. Mouthwashes with CPC reduce the infectivity of SARS-CoV-2 variants in vitro. J Dent Res 2021; 100:1265–1272 [View Article] [PubMed]
     [Google Scholar]
  11. Komine A, Yamaguchi E, Okamoto N, Yamamoto K. Virucidal activity of oral care products against SARS-CoV-2 in vitro. J Oral Maxillofac Surg Med Pathol 2021; 33:475–477 [View Article] [PubMed]
     [Google Scholar]
  12. Xu C, Wang A, Hoskin ER, Cugini C, Markowitz K et al. Differential effects of antiseptic mouth rinses on SARS-CoV-2 infectivity in vitro. Pathogens 2021; 10:272 [View Article] [PubMed]
     [Google Scholar]
  13. Chaudhary P, Melkonyan A, Meethil A, Saraswat S, Hall DL et al. Estimating salivary carriage of severe acute respiratory syndrome coronavirus 2 in nonsymptomatic people and efficacy of mouthrinse in reducing viral load: a randomized controlled trial. J Am Dent Assoc 2021; 152:903–908 [View Article] [PubMed]
     [Google Scholar]
  14. Seneviratne CJ, Balan P, Ko KKK, Udawatte NS, Lai D et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection 2021; 49:305–311 [View Article] [PubMed]
     [Google Scholar]
  15. Elzein R, Abdel-Sater F, Fakhreddine S, Hanna PA, Feghali R et al. In vivo evaluation of the virucidal efficacy of chlorhexidine and povidone-iodine mouthwashes against salivary SARS-CoV-2. A randomized-controlled clinical trial. J Evid Based Dent Pract 2021; 21:101584 [View Article] [PubMed]
     [Google Scholar]
  16. Huang YH, Huang JT. Use of chlorhexidine to eradicate oropharyngeal SARS-CoV-2 in COVID-19 patients. J Med Virol 2021; 93:4370–4373 [View Article] [PubMed]
     [Google Scholar]
  17. Ferrer MD, Barrueco ÁS, Martinez-Beneyto Y, Mateos-Moreno MV, Ausina-Márquez V et al. Clinical evaluation of antiseptic mouth rinses to reduce salivary load of SARS-CoV-2. Sci Rep 2021; 11:24392 [View Article] [PubMed]
     [Google Scholar]
  18. Hiroi S, Kubota-Koketsu R, Sasaki T, Morikawa S, Motomura K et al. Infectivity assay for detection of SARS-CoV-2 in samples from patients with COVID-19. J Med Virol 2021; 93:5917–5923 [View Article] [PubMed]
     [Google Scholar]
  19. Pickering S, Batra R, Merrick B, Snell LB, Nebbia G et al. Comparative performance of SARS-CoV-2 lateral flow antigen tests and association with detection of infectious virus in clinical specimens: a single-centre laboratory evaluation study. Lancet Microbe 2021; 2:e461–e471 [View Article] [PubMed]
     [Google Scholar]
  20. Eduardo FP, Corrêa L, Heller D, Daep CA, Benitez C et al. Salivary SARS-CoV-2 load reduction with mouthwash use: a randomized pilot clinical trial. Heliyon 2021; 7:e07346 [View Article] [PubMed]
     [Google Scholar]
  21. Huang N, Pérez P, Kato T, Mikami Y, Okuda K et al. SARS-CoV-2 infection of the oral cavity and saliva. Nat Med 2021; 27:892–903 [View Article] [PubMed]
     [Google Scholar]
  22. Iorgulescu G. Saliva between normal and pathological. Important factors in determining systemic and oral health. J Med Life 2009; 2:303–307 [PubMed]
     [Google Scholar]
  23. Alzahrani MM, Bamashmous S, Alkharobi H, Alghamdi A, Alharbi RH et al. Mouth rinses efficacy on salivary SARS-CoV-2 viral load: a randomized clinical trial. J Med Virol 2023; 95:e28412 [View Article] [PubMed]
     [Google Scholar]
  24. Seneviratne CJ, Balan P, Ko KKK, Udawatte NS, Lai D et al. Efficacy of commercial mouth-rinses on SARS-CoV-2 viral load in saliva: randomized control trial in Singapore. Infection 2021; 49:305–311 [View Article] [PubMed]
     [Google Scholar]
  25. Brunello G, Wolf V, Kerberger R, Bernhard M, Lübke N et al. Eligibility and efficacy of a CPC- and CHX-based antiviral mouthwash for the elimination of SARS-CoV-2 from the saliva: a randomized, double-blind, controlled clinical trial. J Clin Periodontol 2024; 51:158–166 [View Article] [PubMed]
     [Google Scholar]
  26. Tarragó-Gil R, Gil-Mosteo MJ, Aza-Pascual-Salcedo M, Alvarez MJL, Ainaga RR et al. Randomized clinical trial to assess the impact of oral intervention with cetylpyridinium chloride to reduce salivary SARS-CoV-2 viral load. J Clin Periodontol 2023; 50:288–294 [View Article] [PubMed]
     [Google Scholar]
/content/journal/acmi/10.1099/acmi.0.000722.v3
Loading
Investigating the effectiveness of commercially available mouthwash on SARS-CoV-2 in vivo using viable virus titre as the primary outcome. A randomised controlled trial
Access Microbiology 6, 000722.v3 (2024); https://doi.org/10.1099/acmi.0.000722.v3
/content/journal/acmi/10.1099/acmi.0.000722.v3
/content/journal/acmi/10.1099/acmi.0.000722.v3
Loading

Data & Media loading...

Most cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An error occurred
Approval was partially successful, following selected items could not be processed due to error